| Identification | Back Directory | [Name]
2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxybenzenesulfonamide | [CAS]
474960-44-6 | [Synonyms]
CS-1139
SB 657510
2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxybenzenesulfonamide
2-bromo-N-[4-chloro-3-[(3R)-1-methylpyrrolidin-3-yl]oxy-phenyl]-4,5-dimethoxy-benzenesulfonamide
BenzenesulfonaMide, 2-broMo-N-[4-chloro-3-[[(3R)-1-Methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-diMethoxy- | [Molecular Formula]
C19H22BrClN2O5S | [MDL Number]
MFCD16618389 | [MOL File]
474960-44-6.mol | [Molecular Weight]
505.81 |
| Chemical Properties | Back Directory | [Boiling point ]
585.0±60.0 °C(Predicted) | [density ]
1.512±0.06 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: ≥30mg/mL | [form ]
powder | [pka]
6.60±0.10(Predicted) | [color ]
white to off-white |
| Hazard Information | Back Directory | [Uses]
SB 657510 is a selective GPR14 (urotensin-II (UT) receptor) antagonist. | [Biological Activity]
SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.1 ''SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease statesincluding heart failureatherosclerosishypertension. | [in vivo]
SB-657510 inhibits the progression of high-fat diet induced atherosclerosis and diabetes-associated atherosclerosis[1].
Levels of phosphorylated ERK are significantly attenuated in the aorta of SB-657510-treated (30 mg/kg/day) diabetic mice (Male Apoe KO mice)[3]. | [storage]
Store at RT |
|
| Company Name: |
Grader reagent
|
| Tel: |
18221735425 |
| Website: |
www.shxinping.net |
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|